WuXi Discovery Services

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The mechanisms for resistance to paclitaxel include drug efflux transporter overexpression, altered apoptotic gene expression, and changes associated with microtubules to reduce the influence of this chemotherapeutic agent. The development of targeted therapies for overcoming paclitaxel resistance represents an unmet medical need. To support research in this area, WuXi AppTec has established gastric cancer and breast cancer paclitaxel-resistant tumor models. Click this link 👇 to learn more: https://lnkd.in/eRmVHv_W #DrugDiscovery #DrugResistance #Paclitaxel #Oncology #Antitumor #Taxane #Taxol

As part of our neurobiology services platform, WuXi AppTec offers a comprehensive panel of advanced technologies and validated disease models to help project teams overcome the challenges in predicting the efficacy and safety of their lead candidates. We provide a full spectrum of neurological coverage, from neurodegenerative diseases and neuropsychiatric disorders to sensory and rare disorders. Our in-depth analytics allows researchers to harness the insights of behavioral and neurophysiological assessments for a data-driven approach to drug discovery. Click👇the link below to view our case studies, including the application of a clinical biomarker in a mouse model for Alzheimer’s. https://lnkd.in/ed4m8KQk #DrugDiscovery #CNS #Neurobiology #Neurodegenerative #Neurosensory

Toll-like receptor 8 (TLR8) plays an essential role in human antiviral immunity by recognizing ssRNA of viruses. Upon activation by specific ligands, TLR8 can trigger potent antiviral responses. Development of an in vivo preclinical model has the potential to greatly accelerate research focused on new anti-HBV agents. However, rodent TLR8 is unresponsive to human TLR8 ligands unless polyT-oligodeoxynucleotides are present. To overcome this hurdle, WuXi Biology has established a human TLR8 transgenic mouse model of AAV/HBV infection. At this year’s International HBV Meeting in Chicago, our scientists presented a poster showing that treatment of a TLR8 agonist in this model resulted in significant reductions of plasma HBV DNA, hepatitis B surface antigen (HBsAg) and hepatitis B e-antigen (HBeAg) levels, demonstrating the suitability of this model for evaluating TLR8 modulators. Click this link 👇 to view our poster: https://lnkd.in/eNqAd4Wg #Biotech #DrugDiscovery #HBV #TLR8 #HBsAg #HBeAg

Mark your calendar for our upcoming webinar! With advancements in drug design, there is resurging interest in drugs that form covalent bonds with their targets, often referred to as targeted covalent inhibitors (TCIs). Covalent drugs have the potential to provide enhanced potency and prolonged duration of action compared to non-covalent drugs. In this webinar, our experts will discuss innovative approaches to screen for covalent binders, strategies for the synthesis of covalent warheads, and assays to optimize the ADME/DMPK properties of these molecules. Don’t miss your chance to ask questions to our experts! Click 👇 this link to register for our webinar: https://lnkd.in/eKfRcfkY #DrugDiscovery #Biotech #Covalent #CovalentBinding #TCI

Inositol-requiring enzyme 1α (IRE1α) is a sensor protein that plays a key role in multiple myeloma (MM) and is considered a potential therapeutic target for this type of blood cancer. IRE1α is activated by ER stress, which is common in MM cells due to their high protein synthesis. WuXi AppTec recently contributed to a study which identified a potent and selective IRE1α inhibitor, designated G-5758, that was well tolerated following multiday oral administration. Significantly, G-5758 demonstrated comparable pharmacodynamic effects to induced IRE1 knockdown in a KMS-11 multiple myeloma model. Click this link 👇 to view the abstract: https://lnkd.in/eq4YGias #Biotech #DrugDiscovery #IRE1 #MultipleMyeloma #IRE1alpha

Viruses have well-established causal roles in numerous human cancers. Approximately 10% of cancers globally are attributed to viral infections, primarily from viruses like HPV, EBV, HBV, and HCV. Since viral cancers have viral-specific targets and biomarkers, there is great potential to use these targets as specific antigens for cancer immune therapy. WuXi AppTec offers a broad panel of oncogenic virus-related tumor models and services. Our in vivo platform is comprised of syngeneic, CDX, and PDX models, representing multiple cancer types including lymphoma, cervical cancer, and liver cancer. Click this link 👇 to learn more: https://lnkd.in/eUC5fyiJ #Oncovirus #HPV #EBV #HBV #HCV #PDX #CDX #Syngeneic #Oncogenic

🌍🔬 Exciting things are happening around the world with WuXi Discovery Services! Check out our Global Events Page to see where you can find us next, from international conferences to specialized industry workshops. Whether you're attending to explore cutting-edge advancements in drug discovery or to connect with our experts, we’re looking forward to sharing insights that accelerate your work. 👉 Explore upcoming events here: https://lnkd.in/eEZqAY2K Don't miss the opportunity to connect with us at an event near you! #DrugDiscovery #PharmaEvents #Biotech #WuXiDiscoveryServices

Will you be in Chicago this October 5th-9th? Join WuXi AppTec at booth 533 and talk to one of our experts! WuXi AppTec is proud to present a poster entitled "Finding the right path to psychedelic studies in animals". As part of our drug discovery platform, we offer a comprehensive panel of in vitro assays and in vivo models to help CNS project teams overcome the challenges in predicting the efficacy and safety of their lead candidates. Questions? Prearrange a meeting with an expert here: https://ow.ly/GXk050Tsf2F #SfN #drugdevelopment #drugdevelopment #biotech #biotechnology #neuroscience #Neuroscience2024

Now available to view on demand! In our latest webinar, experts discuss recent advancements in peptide drug discovery, including the evolution of mRNA display and peptide DNA-encoded library (DEL) technology for hit generation and selection, as well as novel cyclization techniques for peptide conformational rigidity. This webinar offers a comprehensive perspective on strategies that are crucial to achieve the desired binding affinity and efficacy for developing potent and orally available peptide drugs. Click this link👇to view the video: https://lnkd.in/eDVhvjM9 #DrugDiscovery #Biotech #Peptide #CyclicPeptide #DEL #mRNAdisplay